{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antipsychotic",
    "query": {
      "intervention": "Antipsychotic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 380,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antipsychotic&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T12:19:12.067Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00167154",
      "title": "Risperidone and Suicidality in Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Risperidone and placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "19 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-06",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167154"
    },
    {
      "nct_id": "NCT05431595",
      "title": "Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Delirium",
        "Epileptics",
        "Neuroleptics"
      ],
      "interventions": [
        {
          "name": "Haloperidol",
          "type": "DRUG"
        },
        {
          "name": "Chlorpromazine",
          "type": "DRUG"
        },
        {
          "name": "Valproate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-07-19",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05431595"
    },
    {
      "nct_id": "NCT04421456",
      "title": "Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "GWP42003-P",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 95,
      "start_date": "2020-08-18",
      "completion_date": "2022-03-16",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 19,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421456"
    },
    {
      "nct_id": "NCT00014001",
      "title": "CATIE- Schizophrenia Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "perphenazine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "quetiapine",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "clozapine",
          "type": "DRUG"
        },
        {
          "name": "fluphenazine decanoate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1600,
      "start_date": "2000-12",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2015-06-17",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 54,
      "location_summary": "Chula Vista, California • Los Angeles, California • Orange, California + 45 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014001"
    },
    {
      "nct_id": "NCT02184767",
      "title": "Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BiPolar"
      ],
      "interventions": [
        {
          "name": "ADASUVE®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-07",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-12",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184767"
    },
    {
      "nct_id": "NCT07570875",
      "title": "Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Ketogenic foodstuffs",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard of Care Oral antipsychotics",
          "type": "OTHER"
        },
        {
          "name": "Standard of care long acting injectable medication for bipolar disorder",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-10",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Montgomery, Alabama",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07570875"
    },
    {
      "nct_id": "NCT01686815",
      "title": "Cross-Sectional Iloperidone IVGTT",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Serious Mental Illness",
        "Metabolic Syndrome",
        "Insulin Resistance",
        "Glucose Metabolism"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2012-10",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01686815"
    },
    {
      "nct_id": "NCT05890768",
      "title": "Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychosis"
      ],
      "interventions": [
        {
          "name": "Lumateperone",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-05-11",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05890768"
    },
    {
      "nct_id": "NCT06245213",
      "title": "A Study of ANAVEX3-71 in Adults With Schizophrenia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ANAVEX3-71 oral capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anavex Life Sciences Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 71,
      "start_date": "2024-03-15",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Marlton, New Jersey",
      "locations": [
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06245213"
    },
    {
      "nct_id": "NCT00903916",
      "title": "Effect of Antipsychotics on Appetite Regulation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Psychotic Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 45,
      "start_date": "2007-08",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-04-03",
      "last_synced_at": "2026-09-22T12:19:12.067Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903916"
    }
  ]
}